Lanreotide studies: 110 papers with results
Page 3 of 3
Lanreotide has 908 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.
- Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.
Shimon I · The Journal of clinical investigation · 1997
In vitro (cells) · 1 result
- Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I · The Journal of clinical investigation · 1997
In vitro (cells) · 1 result
- Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.
Florio T · European journal of endocrinology · 1999
In vitro (cells) · 3 results
- Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
Kidd M · Cancer · 2008
In vitro (cells) · 5 results
- Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin.
Kidd M · Journal of molecular endocrinology · 2007
In vitro (cells) · 2 results
- Agonist-biased trafficking of somatostatin receptor 2A in enteric neurons.
Zhao P · The Journal of biological chemistry · 2013
In vitro (cells) · mouse · 3 results
- The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.
Lo Nigro C · BJU international · 2008
In vitro (cells) · 3 results
- Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid.
Zatelli MC · The Journal of clinical endocrinology and metabolism · 2005
In vitro (cells) · 2 results
- Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues.
Bo Q · Cell discovery · 2022
In vitro (cell-free) · 3 results
- Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional.
Johanson V · Patient preference and adherence · 2012
Not a test of Lanreotide alone · 2 results